Literature DB >> 3663477

Evaluation of immunoreactivity with monoclonal antibody NCRC 11 in breast carcinoma.

I O Ellis1, J Bell, J M Todd, M Williams, C Dowle, A R Robins, C W Elston, R W Blamey, R W Baldwin.   

Abstract

Immunocytochemical staining with monoclonal antibody NCRC 11 of formalin fixed paraffin embedded tumour tissue has been studied in 444 cases of primary breast cancer with a minimum follow period of 6 years. The relationship between extent of staining, assessed on a four point scale, and patient survival has been confirmed. There are significant relationships between staining and both histological grade and oestrogen receptor status. No association has been shown between staining and lymph node stage or tumour size. Simplification of staining assessment by modification to two staining groups still allows significant separation of patients into prognostic groups and incorporation into an existing prognostic index.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3663477      PMCID: PMC2002198          DOI: 10.1038/bjc.1987.192

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  14 in total

1.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

2.  Immunogold-silver staining: new method of immunostaining with enhanced sensitivity.

Authors:  C S Holgate; P Jackson; P N Cowen; C C Bird
Journal:  J Histochem Cytochem       Date:  1983-07       Impact factor: 2.479

3.  Prognostic value of surface antigens in primary human breast carcinomas, detected by monoclonal antibodies.

Authors:  B B Rasmussen; B V Pedersen; S M Thorpe; J Hilkens; J Hilgers; C Rose
Journal:  Cancer Res       Date:  1985-03       Impact factor: 12.701

4.  Estrogen receptor assay in primary breast cancer and early recurrence of the disease.

Authors:  P V Maynard; R W Blamey; C W Elston; J L Haybittle; K Griffiths
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

5.  The assessment of histological differentiation in breast cancer.

Authors:  C W Elston
Journal:  Aust N Z J Surg       Date:  1984-02

6.  The prognostic significance of two epithelial membrane antigens expressed by human mammary carcinomas.

Authors:  M J Wilkinson; A Howell; M Harris; J Taylor-Papadimitriou; R Swindell; R A Sellwood
Journal:  Int J Cancer       Date:  1984-03-15       Impact factor: 7.396

7.  Immunocytochemical staining of breast carcinoma with the monoclonal antibody NCRC 11: a new prognostic indicator.

Authors:  I O Ellis; C P Hinton; J MacNay; C W Elston; A Robins; A A Owainati; R W Blamey; R W Baldwin; B Ferry
Journal:  Br Med J (Clin Res Ed)       Date:  1985-03-23

8.  The prognostic value of the monoclonal antibodies HMFG1 and HMFG2 in breast cancer.

Authors:  N Berry; D B Jones; J Smallwood; I Taylor; N Kirkham; J Taylor-Papadimitriou
Journal:  Br J Cancer       Date:  1985-02       Impact factor: 7.640

9.  A prognostic index in primary breast cancer.

Authors:  J L Haybittle; R W Blamey; C W Elston; J Johnson; P J Doyle; F C Campbell; R I Nicholson; K Griffiths
Journal:  Br J Cancer       Date:  1982-03       Impact factor: 7.640

10.  Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.

Authors:  H J BLOOM; W W RICHARDSON
Journal:  Br J Cancer       Date:  1957-09       Impact factor: 7.640

View more
  13 in total

Review 1.  Preoperative assessment of prognostic factors in breast cancer.

Authors:  H Denley; S E Pinder; C W Elston; A H Lee; I O Ellis
Journal:  J Clin Pathol       Date:  2001-01       Impact factor: 3.411

2.  The Nottingham Prognostic Index in primary breast cancer.

Authors:  M H Galea; R W Blamey; C E Elston; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1992       Impact factor: 4.872

3.  Node negative breast cancer.

Authors:  R W Blamey; C W Elston; I O Ellis; D A Morgan; J L Haybittle
Journal:  BMJ       Date:  1990-04-28

4.  Cellular effects of tamoxifen in primary breast cancer.

Authors:  J F Robertson; I O Ellis; R I Nicholson; A Robins; J Bell; R W Blamey
Journal:  Breast Cancer Res Treat       Date:  1992-01       Impact factor: 4.872

5.  Critical evaluation of monoclonal antibody staining in breast carcinoma.

Authors:  D M Parham; G Coghill; A J Robertson
Journal:  J Clin Pathol       Date:  1989-08       Impact factor: 3.411

6.  Expression of MUC2 epithelial mucin in breast carcinoma.

Authors:  M D Walsh; M A McGuckin; P L Devine; B G Hohn; R G Wright
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

7.  Detection of polymorphic epithelial mucins in the serum of systemic breast cancer patients using the monoclonal antibody, NCRC-11.

Authors:  M R Price; A J Clarke; J F Robertson; C O'Sullivan; R W Baldwin; R W Blamey
Journal:  Cancer Immunol Immunother       Date:  1990       Impact factor: 6.968

8.  Response of breast carcinoma to endocrine therapy predicted using immunostained pelleted fine needle aspirates.

Authors:  E Heyderman; S R Ebbs; S E Larkin; B M Brown; A M Haines; T Bates
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

Review 9.  The 1989 Walter Hubert lecture. Does biological understanding influence surgical practice?

Authors:  R Blamey
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

10.  Assessment of milk fat globule membrane antibodies and lectins as markers of short-term prognosis in breast cancer.

Authors:  R A Walker
Journal:  Br J Cancer       Date:  1990-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.